| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Lotus Pharmaceutical Co Ltd (TW: 1795)
1795 Technical Analysis
1.5
| As on 7th Nov 2025 1795 STOCK Price closed @ 279.00 and we RECOMMEND Buy for LONG-TERM with Stoploss of 268.62 & Sell for SHORT-TERM with Stoploss of 289.76 we also expect STOCK to react on Following IMPORTANT LEVELS. |
1795STOCK Price
| Open | 285.00 | Change | Price | % |
| High | 288.50 | 1 Day | -6.00 | -2.11 |
| Low | 279.00 | 1 Week | -7.00 | -2.45 |
| Close | 279.00 | 1 Month | 87.00 | 45.31 |
| Volume | 1775607 | 1 Year | -22.00 | -7.31 |
| 52 Week High 317.00 | 52 Week Low 176.00 | ||||
TW Taiwan Most Active Stocks
| 2888 | 11.80 | 3.96% |
| 1314 | 9.42 | -3.38% |
| 2337 | 35.25 | 2.32% |
| 2408 | 147.00 | -0.68% |
| 8110 | 28.85 | 9.90% |
| 8021 | 128.50 | 5.33% |
| 2884 | 29.60 | -1.17% |
| 1802 | 28.85 | -4.47% |
| 4989 | 44.60 | -5.31% |
| 1303 | 42.55 | 2.16% |
TW Taiwan Top Gainers Stocks
TW Taiwan Top Losers Stocks
| 1795 Daily Charts |
1795 Intraday Charts |
Whats New @ Bazaartrend |
1795 Free Analysis |
|
|
1795 Important Levels Intraday
| RESISTANCE | 297.31 |
| RESISTANCE | 291.44 |
| RESISTANCE | 287.81 |
| RESISTANCE | 284.18 |
| SUPPORT | 273.82 |
| SUPPORT | 270.19 |
| SUPPORT | 266.56 |
| SUPPORT | 260.69 |
1795 Forecast November 2025
| 4th UP Forecast | 369.57 |
| 3rd UP Forecast | 340.52 |
| 2nd UP Forecast | 322.57 |
| 1st UP Forecast | 304.62 |
| 1st DOWN Forecast | 253.39 |
| 2nd DOWN Forecast | 235.43 |
| 3rd DOWN Forecast | 217.48 |
| 4th DOWN Forecast | 188.43 |
1795 Weekly Forecast
| 4th UP Forecast | 310.80 |
| 3rd UP Forecast | 300.60 |
| 2nd UP Forecast | 294.30 |
| 1st UP Forecast | 287.99 |
| 1st DOWN Forecast | 270.01 |
| 2nd DOWN Forecast | 263.70 |
| 3rd DOWN Forecast | 257.40 |
| 4th DOWN Forecast | 247.20 |
1795 Forecast2025
| 4th UP Forecast | 569.01 |
| 3rd UP Forecast | 476 |
| 2nd UP Forecast | 418.51 |
| 1st UP Forecast | 361.02 |
| 1st DOWN Forecast | 196.98 |
| 2nd DOWN Forecast | 139.49 |
| 3rd DOWN Forecast | 82 |
| 4th DOWN Forecast | -11.01 |
Lotus Pharmaceutical Co Ltd ( TW Taiwan Symbol : 1795 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
1795 Business Profile
Lotus Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells medicines in Taiwan, Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, and central nervous system disease. The company also sells and markets a portfolio of over-the-counter medicines. In addition, it engages in wholesale of cosmetics; retail of clinical machines; biotech technological services; and related consulting services. Lotus Pharmaceutical Co., Ltd. was founded in 1966 and is headquartered in Taipei City, Taiwan. Lotus Pharmaceutical Co., Ltd. is a subsidiary of Alvogen Emerging Markets Holdings Limited. Address: No. 277 Song Ren Road, Taipei, Taiwan, 110
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service